Cargando…

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies

The analysis of plasma circulating tumour nucleic acids provides a non-invasive approach to assess disease burden and the genetic evolution of tumours in response to therapy. BRAF splicing variants are known to confer melanoma resistance to BRAF inhibitors. We developed a test to screen cell-free RN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clark, Michael E., Rizos, Helen, Pereira, Michelle R., McEvoy, Ashleigh C., Marsavela, Gabriela, Calapre, Leslie, Meehan, Katie, Ruhen, Olivia, Khattak, Muhammad A., Meniawy, Tarek M., Long, Georgina V., Carlino, Matteo S., Menzies, Alexander M., Millward, Michael, Ziman, Melanie, Gray, Elin S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646833/ https://www.ncbi.nlm.nih.gov/pubmed/33216826 http://dx.doi.org/10.18632/oncotarget.27790

Ejemplares similares

The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond BRAF Mutant Detection
por: Marsavela, Gabriela, et al.
Publicado: (2020)

Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma
por: Warburton, L., et al.
Publicado: (2020)

Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression
por: Marsavela, Gabriela, et al.
Publicado: (2021)

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
por: McEvoy, Ashleigh C., et al.
Publicado: (2018)

Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells
por: Aya-Bonilla, Carlos Alberto, et al.
Publicado: (2020)

Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study
por: Khattak, Muhammad A., et al.
Publicado: (2020)

Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma
por: McEvoy, Ashleigh C., et al.
Publicado: (2017)

Locus‐specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma
por: Calapre, Leslie, et al.
Publicado: (2018)

Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies
por: McEvoy, Ashleigh C., et al.
Publicado: (2019)

PD‐L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study
por: Khattak, Muhammad A., et al.
Publicado: (2019)

Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device
por: Aya-Bonilla, Carlos A., et al.
Publicado: (2017)

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma
por: Gray, Elin S., et al.
Publicado: (2015)

Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report
por: Calapre, Leslie, et al.
Publicado: (2019)

Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression
por: Warburton, Lydia, et al.
Publicado: (2020)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
por: Pupo, Gulietta M., et al.
Publicado: (2017)

Genetic analysis of heterogeneous subsets of circulating tumour cells from high grade serous ovarian carcinoma patients
por: Asante, Du-Bois, et al.
Publicado: (2023)

Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment
por: Gray, Elin S, et al.
Publicado: (2015)

Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma
por: Beasley, Aaron, et al.
Publicado: (2018)

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series
por: Carlino, Matteo S, et al.
Publicado: (2016)

Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring
por: Klinac, Dragana, et al.
Publicado: (2013)

Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy
por: Abed, Afaf, et al.
Publicado: (2020)

SIRT1 activation mediates heat-induced survival of UVB damaged Keratinocytes
por: Calapre, Leslie, et al.
Publicado: (2017)

Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients
por: Asante, Du-Bois, et al.
Publicado: (2021)

Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells
por: Freeman, James B, et al.
Publicado: (2012)

A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision
por: Stark, Mitchell S., et al.
Publicado: (2019)

Dynamic Landscape of Extracellular Vesicle-Associated Proteins Is Related to Treatment Response of Patients with Metastatic Breast Cancer
por: Ruhen, Olivia, et al.
Publicado: (2021)

Heat-mediated reduction of apoptosis in UVB-damaged keratinocytes in vitro and in human skin ex vivo
por: Calapre, Leslie, et al.
Publicado: (2016)

Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
por: Acheampong, Emmanuel, et al.
Publicado: (2019)

Detection of metastases using circulating tumour DNA in uveal melanoma
por: Beasley, Aaron B., et al.
Publicado: (2023)

Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies
por: Calapre, Leslie, et al.
Publicado: (2023)

Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
por: Irvine, Mal, et al.
Publicado: (2018)

Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles
por: Aya-Bonilla, Carlos, et al.
Publicado: (2019)

Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma
por: Klinac, Dragana, et al.
Publicado: (2014)

Feasibility of supervised telehealth exercise for patients with advanced melanoma receiving checkpoint inhibitor therapy
por: Crosby, Brendan J., et al.
Publicado: (2023)

Resistance to c-Kit inhibitors in melanoma: insights for future therapies
por: Carlino, Matteo S., et al.
Publicado: (2014)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
por: Diefenbach, Russell J., et al.
Publicado: (2022)

Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease
por: Cronin, Christopher, et al.
Publicado: (2022)

Comparison of Circulating Tumour DNA and Extracellular Vesicle DNA by Low-Pass Whole-Genome Sequencing Reveals Molecular Drivers of Disease in a Breast Cancer Patient
por: Ruhen, Olivia, et al.
Publicado: (2020)

Prognostic Relevance of CCDC88C (Daple) Transcripts in the Peripheral Blood of Patients with Cutaneous Melanoma
por: Dunkel, Ying, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_95h0i7iskkn8b94m580pnm31dj